Tashkent, Uzbekistan (UzDaily.com) - The Indonesian Food and Drug Administration (BPOM) approved the ZF-UZ-VAC2001 vaccine (international name Zifivax). This was announced by the head of BPOM Penny K. Lukito during a press conference organized on the occasion.

Penny K. Lukito noted that the Phase I, II, and III trials of this vaccine showed few side effects, and the vaccine was 81.71% effective 7 days after the 3rd dose of the vaccine.

Phase III studies of the ZF2001 vaccine (registered in Uzbekistan as ZF-UZ-VAC2001) were carried out in the city of Bandung, Indonesia, with the participation of 4000 volunteers. In total, 28,000 volunteers from all over the world took part in the research.

According to Indonesian media reports, the ZF-UZ-VAC2001 vaccine has shown an overall efficacy of 92.92% against the Covid-19 virus. So far, Indonesia has used vaccines such as Bio Pharma, Moderna, Pfizer, AstraZeneca, Sinopharm and CanSino.

Indonesia is a member of the International Pharmaceutical Inspection Co-operation Scheme PIC / S, this system is a body that evaluates the quality of pharmaceuticals during the period of state registration, controls the quality of production. This implies some standardization of requirements for drug testing and guarantees the quality of the product. PIC / S also implies full compliance with the GMP standards in the country.